miércoles, 7 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 24, 2026

Bed Bath & Beyond targets 25% gross margin and low- to mid-single-digit revenue growth in 2026 as integration accelerates

View original at seekingalpha.com
Bed Bath & Beyond targets 25% gross margin and low- to mid-single-digit revenue growth in 2026 as integration accelerates Earnings Call Insights: Bed Bath & Beyond (BBBY) Q4 2025 MANAGEMENT VIEW * Marcus Lemonis, CEO, explained that 2025 was focused on stabilizing and building the base of the business, while 2026 is ab…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Gross margin improved 160 basis points year-over-year to 24.6% in Q4, with full year improvement of 390 basis points to 24.7%, driven by structural changes in freight contracts, returns economics, and pricing discipline

    80% confidence
  • The current plan does not assume a housing recovery, but the ecosystem is positioned to benefit as mortgage rates moderate and transaction volumes return to historical mid-cycle levels

    80% confidence
  • 2025 was focused on stabilizing and building the base of the business, while 2026 is about growing and expanding it within a 3-pillar ecosystem

    80% confidence
  • Home services in Pillar 3 have margins in excess of 40%, while Pillar 2 services carry margins north of 50%

    80% confidence
  • The company is very deliberate and confident in its sequencing

    80% confidence
  • Pillar 1 is largely owned, Pillar 2 focuses on partnerships due to regulatory complexity, and Pillar 3 is targeted for ownership to control customer journey and margin

    80% confidence
  • Consolidated margins could expand above and beyond 30% for the overall ecosystem in the next 36 months, pending acquisitions

    80% confidence
  • By Q4 2026, assuming integration milestones are achieved, the company expects positive top line growth and improved margin leverage with an opportunity for profitability

    80% confidence
  • Q1 2026 is expected to see year-over-year revenue growth and at least 30% EBITDA improvement compared to Q1 2025

    80% confidence
  • The company is seeing low to mid-single-digit year-over-year revenue growth increases early in 2026 and targeting this level for the full year

    80% confidence
  • The company expects continued year-over-year improvement in 2026, but that improvement will not be linear

    80% confidence
  • The low to mid-single-digit revenue growth target is for e-commerce only, and Kirkland's will have similar growth at the same time

    80% confidence
  • The company is targeting 3% to 5% revenue improvement in Q1 2026 and a 30% improvement in EBITDA margin year-over-year for the same period

    80% confidence
  • The trough in active customer base is behind the company, and everything going forward will show growth in revenue, EBITDA performance, and number of active customers

    80% confidence
  • Revenue declined 10% year-over-year in Q4, with 6% decline excluding Canada discontinuation, while AOV improved 7% driven by improved assortment and increased Overstock sales mix

    80% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,986
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,986 hechos verificados con la fuente5,362 documentos fuente archivados
Consulta estos datos → isubstrate.com